C S Zent

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data
    C S Zent
    Division of Hematology Oncology, Departments of Medicine and Pathology, Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 92:1325-30. 2001
  2. ncbi The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype
    Clive S Zent
    Division of Hematology Oncology, Central Arkansas Healthcare System and University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
    Leuk Res 27:765-74. 2003
  3. ncbi Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
    L Joseph
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Am J Hematol 68:287-91. 2001
  4. ncbi Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia
    Shanique Palmer
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 141:607-14. 2008
  5. ncbi MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?
    Tait D Shanafelt
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Leuk Res 32:1458-61. 2008
  6. ncbi Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
    Rebekah L Browning
    Ohio State University, Columbus, OH, United States
    Leuk Res 31:1737-40. 2007
  7. ncbi Chronic B-cell lymphoproliferative disorders: how many diseases?
    Clive S Zent
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leuk Lymphoma 47:2006-7. 2006
  8. ncbi Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
  9. ncbi Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes
    Elizabeth H Nora
    Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA
    South Med J 99:876-9. 2006
  10. ncbi Update on monoclonal antibody therapy in chronic lymphocytic leukemia
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Adv Hematol Oncol 2:107-13. 2004

Collaborators

Detail Information

Publications12

  1. ncbi Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data
    C S Zent
    Division of Hematology Oncology, Departments of Medicine and Pathology, Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 92:1325-30. 2001
    ..Tumor registry data may underestimate the incidence of CLL substantially because CLL can be diagnosed by flow cytometric analysis of peripheral blood cells, and the majority of patients do not require treatment at the time of diagnosis...
  2. ncbi The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype
    Clive S Zent
    Division of Hematology Oncology, Central Arkansas Healthcare System and University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
    Leuk Res 27:765-74. 2003
    ..CLL and MM differentially expressed 18% of 130 apoptosis related genes, suggesting differences in mechanisms of cell survival...
  3. ncbi Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
    L Joseph
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Am J Hematol 68:287-91. 2001
    ..The diagnosis of herpes simplex lymphadenitis in patients with CLL/SLL is especially important because, unlike large cell transformation, the infection usually responds well to treatment...
  4. ncbi Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia
    Shanique Palmer
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 141:607-14. 2008
    ..These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted...
  5. ncbi MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?
    Tait D Shanafelt
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Leuk Res 32:1458-61. 2008
    ..In contrast, CD38 predicted TTT (p=0.02) regardless of the proposed new classification. Molecular characteristics of the leukemic clone are a better predictor of progression than an arbitrary ALC or B lymphocyte count threshold...
  6. ncbi Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
    Rebekah L Browning
    Ohio State University, Columbus, OH, United States
    Leuk Res 31:1737-40. 2007
    ..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted...
  7. ncbi Chronic B-cell lymphoproliferative disorders: how many diseases?
    Clive S Zent
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leuk Lymphoma 47:2006-7. 2006
  8. ncbi Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
    ....
  9. ncbi Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes
    Elizabeth H Nora
    Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA
    South Med J 99:876-9. 2006
    ..Key features in his history and physical examination prompted the conclusive testing. The most telling features were hypotension, tachycardia, and the rash (urticaria pigmentosa)...
  10. ncbi Update on monoclonal antibody therapy in chronic lymphocytic leukemia
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Adv Hematol Oncol 2:107-13. 2004
    ..This review provides historical context and detailed analysis of current developments, as well as an outline for future prospects and expectations in this exciting new arena of therapeutics...
  11. ncbi Clinical significance of monoclonal B cells in cerebrospinal fluid
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Cytometry B Clin Cytom 63:23-7. 2005
    ..Although flow cytometry is increasingly used to detect a monoclonal B-cell population in the CSF, the significance of this finding in the absence of morphologically identifiable malignant cells is unknown...
  12. ncbi Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 113:2110-8. 2008
    ..In this phase 2 study, the authors tested the safety and efficacy of early treatment for patients with high-risk CLL using alemtuzumab and rituximab...